BACKGROUND: Hepatic veno-occlusive disease (VOD) is a rare and potentially severe complication of chemotherapy. We describe five patients who developed VOD after chemotherapy for Wilms tumor (WT) and evaluate the role of plasminogen activator inhibitor-1 (PAI-1) and defibrotide for diagnosis and therapy of VOD, respectively. PATIENTS AND METHODS: Thirty-five patients treated from 2002 to 2009 for WT were eligible. Diagnosis of VOD was according McDonald's criteria that required two of the following: jaundice, hepatomegaly and/or right upper quadrant pain, weight gain with or without ascites. RESULTS: VOD occurred in 5 of 35 patients (14%) after 21-105 days from starting chemotherapy. Two patients developed multiorgan failure (MOF). PAI-1 was high in four patients who were tested. Three patients were treated with defibrotide and no side effects were reported while two patients received supportive measures only. Four patients recovered and three of them received defibrotide. They are all alive and well after a median follow-up of 35 months. One of two patients not treated with defibrotide died of MOF. CONCLUSIONS: PAI-1 levels were abnormal in WT-VOD. Defibrotide was a safe, well-tolerated, and potentially efficacious therapy in this group of patients. Further prospective study is needed in WT-VOD to confirm these data.
BACKGROUND:Hepatic veno-occlusive disease (VOD) is a rare and potentially severe complication of chemotherapy. We describe five patients who developed VOD after chemotherapy for Wilms tumor (WT) and evaluate the role of plasminogen activator inhibitor-1 (PAI-1) and defibrotide for diagnosis and therapy of VOD, respectively. PATIENTS AND METHODS: Thirty-five patients treated from 2002 to 2009 for WT were eligible. Diagnosis of VOD was according McDonald's criteria that required two of the following: jaundice, hepatomegaly and/or right upper quadrant pain, weight gain with or without ascites. RESULTS: VOD occurred in 5 of 35 patients (14%) after 21-105 days from starting chemotherapy. Two patients developed multiorgan failure (MOF). PAI-1 was high in four patients who were tested. Three patients were treated with defibrotide and no side effects were reported while two patients received supportive measures only. Four patients recovered and three of them received defibrotide. They are all alive and well after a median follow-up of 35 months. One of two patients not treated with defibrotide died of MOF. CONCLUSIONS:PAI-1 levels were abnormal in WT-VOD. Defibrotide was a safe, well-tolerated, and potentially efficacious therapy in this group of patients. Further prospective study is needed in WT-VOD to confirm these data.
Authors: Zofia Szmit; Ewa Gorczynska; Anna Król; Marek Ussowicz; Monika Mielcarek-Siedziuk; Igor Olejnik; Anna Panasiuk; Krzysztof Kałwak Journal: Bone Marrow Transplant Date: 2020-05-12 Impact factor: 5.483
Authors: S Corbacioglu; E Carreras; M Ansari; A Balduzzi; S Cesaro; J-H Dalle; F Dignan; B Gibson; T Guengoer; B Gruhn; A Lankester; F Locatelli; A Pagliuca; C Peters; P G Richardson; A S Schulz; P Sedlacek; J Stein; K-W Sykora; J Toporski; E Trigoso; K Vetteranta; J Wachowiak; E Wallhult; R Wynn; I Yaniv; A Yesilipek; M Mohty; P Bader Journal: Bone Marrow Transplant Date: 2017-07-31 Impact factor: 5.483
Authors: Rishi S Kotecha; Amy Buckland; Marianne B Phillips; Catherine H Cole; Nicholas G Gottardo Journal: J Pediatr Hematol Oncol Date: 2014-01 Impact factor: 1.289